Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 24, 2007

Novozymes Creates Biopharmaceutical Ingredients Business

  • Novozymes set up a biopharmaceutical ingredients business to develop and manufacture animal-free recombinant ingredients to support production. The initial focus will be the launch of a range of ingredients developed specifically for industrial-scale mammalian cell culture.

    “We are very excited by the launch of this new business and what it represents to the wider biopharmaceutical industry”, says Peter Rosholm, vp for the iIngredients business area. “We have combined Novozymes expertise in large-scale protein production and supply with a strong science base to provide a range of products specifically developed for biopharmaceutical production.

    “In addition to addressing the need to produce ever-safer biopharmaceuticals, our cell culture range has a secure supply network to deliver ingredients that allow for process optimization whilst reducing customers regulatory and lot testing burdens.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »